Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Licenses Chemotherapy Management Technology from Saladax

NEW YORK (GenomeWeb News) – Myriad Genetics said today it has licensed pharmacokinetic analysis technology from Saladax Biomedical for use in chemotherapy drug management.
 
Under the agreement, Myriad has gained an exclusive North American license for Saladax technology that allows doctors to personalize chemotherapy doses to improve the efficacy of the treatment and to minimize toxicity, the company said.
 
Myriad President Gregory Critchfield said in a statement that the technology will “complement our current product portfolio and will be readily sold through our existing 150-person oncology salesforce.”
 
Financial terms of the agreement were not released.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.